What Lixisenatide is
Lixisenatide is a GLP-1 receptor agonist used in approved metabolic-disease contexts.
Lixisenatide is grouped under Fat Loss + GLP-1s / Approved / Clinical on PeptideFactCheck because it rounds out the GLP-1 map and shows how much broader the incretin category is than the newest blockbuster names.
The useful starting point is to separate the molecule itself from the internet story around it. It rounds out the GLP-1 map and shows how much broader the incretin category is than the newest blockbuster names.
Why people keep looking it up
It rounds out the GLP-1 map and shows how much broader the incretin category is than the newest blockbuster names.
Lixisenatide is a GLP-1 receptor agonist used in approved metabolic-disease contexts.
Lixisenatide tends to stay in the conversation because it touches a familiar public theme: glp-1 receptor, glucose control, and appetite signaling. That makes it easy for the claim to travel faster than the evidence.
What the evidence can support right now
Regulated GLP-1 therapy with source-backed human evidence.
Human trials and labeling support specific approved use cases.
Mechanistic support follows established GLP-1 receptor biology.
Why this page carries the current tier: Regulated GLP-1 therapy with source-backed human evidence.
The current seed trail for Lixisenatide is pulling from 1 labels source, 1 regulatory source, and 1 literature source.
Safety, limits, and regulatory context
Approved does not erase the need to read route, contraindication, and warning sections directly from labels.
FDA-approved lixisenatide products exist or have existed for specific indications depending on market timing.
Editorial boundary: PeptideFactCheck does not publish dosing, cycling, sourcing, injection, or administration instructions for Lixisenatide. The job here is to explain the public claim, the mechanism story, the evidence strength, and the current limits.
Molecular and identifier data
The current PubChem match for Lixisenatide is CID 90472060. That gives the page a source-backed chemistry record rather than a placeholder identifier block.
- PubChem CID
- 90472060
- Formula
- C215H347N61O65S
- Molecular weight
- 4858
- InChIKey
- XVVOERDUTLJJHN-IAEQDCLQSA-N
Matched synonyms include Lixisenatide, Adlyxin, Lyxumia, ZP10A peptide, 320367-13-3, ZP 10, AVE0010, AQVE-10010.
Open PubChem recordClinical trial snapshot
The current ClinicalTrials.gov intervention query for Lixisenatide returns 75 study records. This does not prove efficacy by itself, but it does show whether the peptide is showing up in a formal trial registry rather than only in forums or vendor copy.
Literature snapshot
The current PubMed query for Lixisenatide returns 724 results. The articles below are a quick literature surface so the page shows actual papers instead of only generic evidence labels.
Label and regulatory records
For approved or clinically developed peptides, the page now pulls in official labeling and FDA-facing records where they exist. That makes the regulatory section materially more useful than a generic approved or not-approved tag.
- Brand names
- Soliqua 100/33
- Generic names
- INSULIN GLARGINE AND LIXISENATIDE
- Routes
- SUBCUTANEOUS
- Application numbers
- BLA208673
Indications and usage. 1 INDICATIONS AND USAGE SOLIQUA 100/33 is a combination of insulin glargine and lixisenatide and is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. SOLIQUA 100/33 is a combination of insulin glargine, an insulin analog, and lixisenatide, a glucagon-like peptide-1 (GLP-1) receptor agonist, indicated as an adjunct to diet and exercise to improve glycemi...
Warnings and cautions. 5 WARNINGS AND PRECAUTIONS Anaphylaxis and Serious Hypersensitivity Reactions : Severe, life-threatening, and generalized allergic reactions can occur. Instruct patients to discontinue use if a reaction occurs and promptly seek medical attention. ( 5.1 ) Acute Pancreatitis : Has been observed in patients treated with GLP-1 receptor agonists, including SOLIQUA 100/33. Discontinue if pancreatitis is suspected. ( 5.2 )...
Contraindications. 4 CONTRAINDICATIONS SOLIQUA 100/33 is contraindicated: During episodes of hypoglycemia [see Warnings and Precautions (5.6) ] . In patients with serious hypersensitivity to insulin glargine, lixisenatide, or any of the excipients in SOLIQUA 100/33. Hypersensitivity reactions including anaphylaxis have occurred with both lixisenatide and insulin glargine [see Warnings and Precautions (5.1) and Adverse Reactions (6.1)...
Source trail
Each linked source is shown directly so the page can be audited. The page now combines its editorial seed trail with automated official-source enrichment generated on 2026-04-24 from PubChem, ClinicalTrials.gov, PubMed, DailyMed, openFDA label, and Drugs@FDA.